Related references
Note: Only part of the references are listed.Chemotherapy dose reductions in obese patients with colorectal cancer
P. Chambers et al.
ANNALS OF ONCOLOGY (2012)
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Yunwei Han et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study
Olivier Capitain et al.
CLINICAL COLORECTAL CANCER (2012)
Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring
Markus Joerger et al.
CLINICAL PHARMACOKINETICS (2012)
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Target Concentration Intervention in Oncology: Where Are We At?
Mohamed Saleem et al.
THERAPEUTIC DRUG MONITORING (2012)
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy
Kohei Shitara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
Hans Wildiers et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Obesity and Survival Among Black Women and White Women 35 to 64 Years of Age at Diagnosis With Invasive Breast Cancer
Yani Lu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Commentary: Chemotherapy Dosing in Obese Patients With Cancer-The Need for Evidence-Based Clinical Practice Guidelines
Gary H. Lyman
JOURNAL OF ONCOLOGY PRACTICE (2011)
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
Evandro de Azambuja et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass
Deise Raquel Barpe et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Katherine M. Flegal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma
Jeffrey A. Jones et al.
LEUKEMIA & LYMPHOMA (2010)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA)
Rodney J. Hunter et al.
CANCER TREATMENT REVIEWS (2009)
Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2
Joanna Schwartz et al.
GYNECOLOGIC ONCOLOGY (2009)
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
S. V. Barrett et al.
ANNALS OF ONCOLOGY (2008)
Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
Jason D. Wright et al.
GYNECOLOGIC ONCOLOGY (2008)
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey
Kathryn M. Field et al.
JOURNAL OF ONCOLOGY PRACTICE (2008)
Obesity and mortality in men with locally advanced prostate cancer - Analysis of RTOG 85-31
Jason A. Efstathiou et al.
CANCER (2007)
Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer
Peter Jenkins et al.
EUROPEAN JOURNAL OF CANCER (2007)
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer
Udai Banerji et al.
LUNG CANCER (2006)
Effect of obesity on survival in epithelial ovarian cancer
James C. Pavelka et al.
CANCER (2006)
Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma
Sebastien Salas et al.
THERAPEUTIC DRUG MONITORING (2006)
Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
M Colleoni et al.
LANCET (2005)
Undertreatment of obese women receiving breast cancer chemotherapy
JJ Griggs et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Body mass index in relation to ovarian cancer survival
M Zhang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from intergroup trial 0114
JA Meyerhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
JA Meyerhardt et al.
CANCER (2003)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
SD Baker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
FE de Jongh et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Obesity and autologous stem cell transplantation in acute myeloid leukemia
G Meloni et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
